Viewing Study NCT04176848



Ignite Creation Date: 2024-05-06 @ 1:59 PM
Last Modification Date: 2024-10-26 @ 1:23 PM
Study NCT ID: NCT04176848
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2022-06-30
First Post: 2019-11-19

Brief Title: CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Sponsor: Canadian Cancer Trials Group
Organization: Canadian Cancer Trials Group

Study Overview

Official Title: A Phase II Study of CFI-400945 and Durvalumab in Patients With AdvancedMetastatic Triple Negative Breast Cancer TNBC
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-08
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer
Detailed Description: CFI-400945 is a new type of drug for breast cancer Laboratory tests show that it works by blocking a specific protein called Polo-like Kinase 4 PLK4 that is involved in cancer cell growth CFI-400945 may slow down the growth of cancer cells or may cause cancer cells to die This drug has been shown to shrink tumours in animals and has been studied in more than 60 patients It appears to be well tolerated with few side effects CFI-400945 seems promising but it is not clear if it can offer better results than standard therapy

Durvalumab is a new type of drug for many types of cancer Durvalumab is an immunotherapy drug and not a chemotherapy drug Laboratory tests show that it works by allowing the immune system PD-1 and PD-L1 interaction to detect your cancer and reactivating the immune response This may help to slow down the growth of cancer or may cause cancer cells to die Durvalumab has been shown to shrink tumours in animals and has been studied in more than 6000 people In laboratory studies when used together with CFI-400945 results seem promising but it is not clear if it can offer better results than standard treatment alone This is the first time that the combination of CFI-400945 and durvalumab has been tested in patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None